Novartis says wholesale acquisition cost of Zolgensma $2.125M
AveXis, a Novartis company, announced what it called "innovative access programs" for Zolgensma for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy with bi-allelic mutations in the survival motor neuron 1 gene. AveXis said it "is working closely with payers to offer pay-over-time options up to 5 years and outcomes-based agreements up to 5 years, as well as providing a patient program to support affordability and access." The wholesale acquisition cost of Zolgensma is $2.125M, which the company said is 50% of the 10-year cost of current chronic SMA treatment, estimated at $4.1M; 50% below 10-year treatment costs for genetic pediatric ultra-rare diseases, which is estimated at $4.4M-$5.7M; and 50% below the ICER ultra-rare disease cost-effectiveness threshold. Zolgensma pricing places it at approximately $250,000 per quality-adjusted life-year, the company added. "AveXis has partnered with Accredo to offer a pay-over-time option of up to 5 years to help ease possible short-term budget constraints, especially for states, small payers and self-insured employers. In addition, CuraScript SD has been selected as the sole specialty distributor given its rare disease experience, including gene and cell therapies. Reflecting the pioneering nature of these programs, more than 15 payers are in advanced discussions of terms with AveXis, with some having already agreed, in principle, to terms," the company stated following its announcement of FDA approval for Zolgensma.